Medpace Holdings Inc 2025年度报告

August J. TroendleChief Executive Officer andChairman of the Board of DirectorsJesse J. GeigerPresidentSusan E. BurwigExecutive Vice President, OperationsStephen P. EwaldGeneral Counsel and Corporate SecretaryKevin M. BradyChief Financial Officer and Treasurer August J. TroendleChairman of the Board of DirectorsBrian T. CarleyAudit Committee, ChairNominating and Governance CommitteeFred B. Davenport Jr.Lead DirectorCompensation Committee, ChairAudit CommitteeNominating and Governance CommitteeFemida H. Gwadry-SridharNominating and Governance CommitteeRobert O. KraftAudit and Compensation CommitteesNominating and Governance CommitteeCornelius P. "Neal" McCarthy IIICompensation CommitteeNominating and Governance CommitteeDani S. ZanderNominating and Governance Committee Medpace Holdings, Inc.5375 Medpace WayCincinnati, Ohio 45227513-579-9911www.medpace.com Lauren Morris283-227-6409l.morris@medpace.com Deloitte & Touche LLP50 W 5th St.Suite 200Cincinnati, Ohio 45202 Michael Maley283-227-6367m.maley@medpace.com Equiniti Trust Company, LLC718-921-8124Email: HelpAST@equiniti.comequiniti.com/us/ast-access NASDAQ under tickersymbol MEDP The information included in this Annual Report on Form 10-K as filed with the U.S. Securities and ExchangeCommission on February 10, 2026 presents information as of and for the fiscal year ended December 31, 2025 and,accordingly, does not include information for updates or developments that are not required to be otherwise reportedin the Annual Report on Form 10-K for the fiscal year ended December 31, 2025. Securities registered pursuant to Section 12(b) of the Act: Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. Yes†No_ Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during thepreceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.Yes_No† Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes_No† Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerginggrowth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of theExchange Act. If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revisedfinancial accounting standards provided pursuant to Section 13(a) of the Exchange Act.† Indicate by check mark whether the registrant has filed a report on and attestation to its management’s assessment of the effectiveness of its internal control overfinancial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report._ If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflectthe correction of an error to previously issued financial statements.† Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any ofthe registrant’s executive officers during the relevant recovery period pursuant to §240.10D-1(b).† Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes†No_ The aggregate market value of the voting and non‑voting common equity held by non‑affiliates of the registrant, based upon the closing sale price as reported on theNasdaq Global Select Market on June 30, 2025, the last business day of the registrant’s most recently completed second fiscal quarter, was approximately $7.0 billion. Forpurposes of this computation, shares of the registrant’s common stock held by each executive officer, director, and each person known to the registrant to own 10% or more ofthe outstanding voting power reporting such ownership on Schedule 13D have been excluded in that such persons are affiliates. Portions of the registrant's definitive proxy statement to be filed with the Securities and Exchange Commission relating to the 2026 Annual Meeting of Stockholdersare incorporated herein by reference into Part III of this Annual Report on Form 10-K to the extent stated herein. MEDPACE HOLDINGS, INC. AND SUBSIDIARIESANNUAL REPORT ON FORM 10-KFOR FISCAL YEAR ENDED DECE